TOP TIERMARKET NEWSWIRE

News & sentiment

HUMACYTE INC (HUMA) — News & AI sentiment

HUMACYTE INC (HUMA) news roundup. 3 stories in the past week, 12 over 30 days. Average 30-day sentiment is 60.8/100. Recent insider activity (SEC Form 4, 90-day window): 3 purchases totalling $30K and 0 sales totalling $0 — net buying of $30K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

3

avg sentiment 60/100

30d stories

12

avg sentiment 60.8/100

Insider net (90d)

$30K

3 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

HUMA news in the last 24 hours, 7 days, 30 days and 90 days

How much HUMA coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	HUMA stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	3	60/100	HUMA headlines →
Last 30 days	12	60.8/100	HUMA headlines →
Last 90 days	40	56.7/100	HUMA headlines →

Latest stories on HUMA

Humacyte Issued New U S Patent Covering Symvess

The Fly58 · neutralproduct/pr

3d ago

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

GlobeNewswire58 · neutralproduct/pr

3d ago

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

Business Insider64 · neutralproduct/pr

Oct 23

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

GlobeNewswire64 · neutralproduct/pr

Oct 23

Humacyte stock price target reiterated at $1 by StoneX on demand

Investing.com Analyst Ratings50 · neutralanalyst

Oct 16

Humacyte stock gains ordering hospitals, H.C. Wainwright reiterates Buy

Investing.com Analyst Ratings63 · neutralanalyst

Oct 16

Humacyte says hospitals ordering Symvess rose 44% in Q3 to 49

The Fly64 · neutralproduct/pr

Oct 15

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

GlobeNewswire64 · neutralproduct/pr

Oct 15

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

StockTitan63 · neutralproduct/pr

Oct 15

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

GlobeNewswire63 · neutralproduct/pr

Oct 12

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

Business Insider63 · neutralproduct/pr

Oct 12

Humacyte initiated with an Equal Weight at Barclays

The Fly55 · neutralanalyst

Oct 6

Humacyte, Inc. (HUMA) files 8-K

SEC 8-K50 · neutralgeneral

Sep 28

Humacyte announces addition of Coward, Kuznik to board

The Fly55 · neutralgeneral

Sep 28

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

GlobeNewswire55 · neutralgeneral

Sep 28

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

StockTitan56 · neutralgeneral

Sep 28

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire55 · neutralgeneral

Sep 10

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

StockTitan55 · neutralgeneral

Sep 10

Humacyte announces FDA extension of expiration dating period for Symvess

The Fly59 · neutralproduct/pr

Sep 9

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

GlobeNewswire67 · bullishproduct/pr

Sep 9

Humacyte confirms plans for ATEV supplemental biologic license application

The Fly63 · neutralgeneral

Aug 24

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

StockTitan63 · neutralproduct/pr

Aug 24

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

PR Newswire34 · bearishgeneral

Aug 22

Humacyte (HUMA) Q2 2026 Earnings Call Transcript

Yahoo Top63 · neutralearnings

Aug 19

Humacyte (HUMA) Q2 2026 Earnings Call Transcript

The Motley Fool63 · neutralearnings

Aug 19

Open HUMA in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →